Contribution of the AIM2 inflammasome to chronic inflammation in patients with Myelofibrosis.

DE LUCA, G; GOETTE NP GUTIERREZ M, LARRIPA IB, MARTA RF, GLEMBOTSKY AC, HELLER PG. ; LEV PR; CAMACHO MF; CASTRO RÍOS MA; SACKMANN F; MOIRAGHI B; CORTES V; CAULA V; VERRI V; BENDEK G; CARRICONDO E; VICENTE A; VARELA A; VALLEJOS V; CARUSO V; GUTIERREZ M; LARRIPA I; MARTA RF; GLEMBOTSKY AC; HELLER PG

Congreso; LXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; 2022

Myelofibrosis (MF) is a myeloproliferative neoplasm associated with poor outcome. It is caused by driver (JAK2/CALR/MPL) and high-risk mutations (HRM) coupled to a chronic inflammatory process that accentuates the disease. In a previous work we described high levels of cell-free DNA (cfDNA) in MF patients that increase as disease progresses. cfDNA has pro-inflammatory effects being one of its targets the AIM2 inflammasome, responsible for maturation and release of IL-1β and IL-18 and involved in pyroptotic cell death.The aim of this work was to assess the activation of the inflammasome in MF patients and the role of AIM2 in monocytes. IL-18, an inflammasome product, was elevated in plasma from MF patients (n=66) vs. controls (P